Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
about
Current and emerging treatment options in the management of lupusKey issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implicationsFrequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort.Damage in the Multiethnic Malaysian Systemic Lupus Erythematosus (SLE) Cohort: Comparison with Other Cohorts WorldwideValidation of the Lupus Nephritis Clinical Indices in Childhood-Onset Systemic Lupus Erythematosus.Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care.Association of age with health-related quality of life in a cohort of patients with systemic lupus erythematosus: the Georgians Organized Against Lupus study.First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort.Independent association of glucocorticoids with damage accrual in SLE.A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach.Renal histology in Indigenous Australians with lupus nephritis.The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus.Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies.Why targeted therapies are necessary for systemic lupus erythematosus.From Childhood to Adulthood: The Trajectory of Damage in Patients with Childhood-Onset Systemic Lupus Erythematosus.Systemic lupus erythematosus diagnosis and management.It hasn't gone away: the problem of glucocorticoid use in lupus remains.Disease Outcomes and Care Fragmentation Among Patients With Systemic Lupus Erythematosus.Treatment pathways in an inception lupus cohort over the first three years.Prognostic implications of active discoid lupus erythematosus and malar rash at the time of diagnosis of systemic lupus erythematosus: Results from a prospective cohort study.Incidence and prevalence of systemic lupus erythematosus among the native Arab population in UAE.Factors associated with disease expression patterns in systemic lupus erythematosus patients: results from LUMINA (LXXVII), a multiethnic US cohort.Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus.Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry.Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE.Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey.Long-term mortality and morbidity of patients with systemic lupus erythematosus: a single-center cohort study in China.Long-term prognosis and factors associated with damage accrual in Japanese patients with systemic lupus erythematosus.Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register.Musculoskeletal manifestations as determinants of quality of life impairment in patients with systemic lupus erythematosus.Disease Outcomes in Glucocorticosteroid-Naive Patients With Systemic Lupus Erythematosus.Treat-to-target in systemic lupus erythematosus: are we there yet?Glucocorticoid-induced leucine zipper (GILZ) inhibits B cell activation in systemic lupus erythematosus.Risk of damage and mortality in SLE patients fulfilling the ACR or only the SLICC classification criteria. A 10-year, inception cohort study.Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years.The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus.A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.Antimalarial-induced cardiomyopathy: a systematic review of the literature.
P2860
Q26741266-91ED8078-58AF-4BCD-8BB9-E7B3754C30DBQ26775756-19844E41-3F79-43DD-A11E-EE539E33FEACQ36188027-CF325508-7960-4081-88F1-98B86144FAA8Q36192962-C7B95D57-E27C-4855-971B-B58FDE441302Q36484106-A8B65624-CD7B-431D-9256-DD9FBBF1367FQ37121787-AEA0D8C0-B0A7-4FA4-B80A-0AAED0BE0282Q37133875-771B99C0-872D-4BF4-A6CC-B9895DBECA6FQ37177435-5DBD560D-215B-4225-BAF9-6A3994696FD2Q37464030-0204BBC1-BA1B-4101-9E61-214FEAAD6370Q38409092-11B1E690-9664-499A-971D-7911B963ACB0Q38649705-4262FB8F-8A09-44C9-8E31-9534CE98A05DQ38784456-83577847-615A-4FB7-96B0-A966E33D241EQ38800659-CC319025-1853-4866-BA32-DF111EFBEC8CQ38806513-48BFFE80-631A-4183-A323-D30D1815404BQ38920435-02EB4A90-4F7C-41A2-A9FA-DFF0C8368D34Q39001634-C4A2C855-F09D-4187-9CEA-932ECCC06265Q39053129-90717F46-6BD3-4AFD-9217-F7990F31F893Q39053147-0E6E2790-FCCA-4D2D-9E9E-4AC334E4E6B0Q39144976-449501A4-8A4E-4772-A8C5-3DD5815A673CQ39640596-FDC046AC-99D0-4B08-8A31-E7C1118A570BQ40446583-80EA9189-C679-43EA-864F-33A66C31622AQ40481385-C8EC3A8C-67AF-4EB5-B8AA-7A5AB6EED26CQ40608327-612582F8-F36F-4808-9B97-F82B910A5879Q40709092-C5867D7D-F700-4027-9288-7F4139EAD970Q40831626-81BE8CD4-8C8C-46D4-9A13-D59C16C1A538Q47130347-57A6F30F-00A7-4199-93E5-E4ADD3EA85DEQ47133837-5600A22D-4559-4F83-8FDA-8E2B05A781A0Q47199208-ACCAF2B8-4743-4021-AD60-43D5505A9752Q47233650-B99D0934-A097-41D0-85DA-5EEE6B8A94A8Q47687376-3475458E-4F3C-4BF4-94A8-81FC5306B059Q47692440-CEE010DA-F5F1-4E26-B260-FEA58432D427Q47790587-689F92F4-F72B-4CF6-B468-07268621D2A6Q47846085-581E00E9-A795-4DF7-AECB-7D87968F55FCQ48097435-AA995E2E-DC38-486A-AF5C-DDB22B3E41AFQ48317028-8631EBA1-8F62-460E-9B84-CD7C59D79809Q48504730-8A43043D-EF5C-40F3-8C1A-A37A55C6B0E6Q48663436-82AA632E-3BC6-43D8-B4AD-3E5A72DB3A9BQ48854142-E0DC8B84-BF65-4C36-8971-F408AD9888BEQ49359821-25673E10-ED82-415E-B173-5002F9B2568DQ49383501-9D82A1C3-C186-42DB-B8F3-9A61CA59115D
P2860
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Factors associated with damage ...... inics (SLICC) Inception Cohort
@ast
Factors associated with damage ...... inics (SLICC) Inception Cohort
@en
Factors associated with damage ...... inics (SLICC) Inception Cohort
@nl
type
label
Factors associated with damage ...... inics (SLICC) Inception Cohort
@ast
Factors associated with damage ...... inics (SLICC) Inception Cohort
@en
Factors associated with damage ...... inics (SLICC) Inception Cohort
@nl
prefLabel
Factors associated with damage ...... inics (SLICC) Inception Cohort
@ast
Factors associated with damage ...... inics (SLICC) Inception Cohort
@en
Factors associated with damage ...... inics (SLICC) Inception Cohort
@nl
P2093
P2860
P50
P3181
P1476
Factors associated with damage ...... inics (SLICC) Inception Cohort
@en
P2093
Aidan G O'Keeffe
Anisur Rahman
Ann E Clarke
Asad A Zoma
Barri J Fessler
Christine A Peschken
Cynthia Aranow
Daniel J Wallace
Diane L Kamen
Ellen M Ginzler
P2860
P304
P3181
P356
10.1136/ANNRHEUMDIS-2013-205171
P407
P50
P577
2015-09-01T00:00:00Z